sentence1
stringlengths 35
423
| sentence2
stringlengths 34
427
| score
int64 -1
1
|
|---|---|---|
Although this meta-analysis suggests that consumption of fish and foods rich in omega-3 fatty acids may be associated with a lower risk of AMD, there is insufficient evidence from the current literature, with few prospective studies and no randomized clinical trials, to support their routine consumption for AMD prevention. | Although this meta-analysis suggests that consumption of fish and foods rich in omega-3 fatty acids may not be associated with a lower risk of AMD, there is insufficient evidence from the current literature, with few prospective studies and no randomized clinical trials, to support their routine consumption for AMD prevention. | -1 |
Although this meta-analysis suggests that consumption of fish and foods rich in omega-3 fatty acids may be associated with a lower risk of AMD, there is insufficient evidence from the current literature, with few prospective studies and no randomized clinical trials, to support their routine consumption for AMD prevention. | Although this meta-analysis suggests that consumption of fish and foods rich in omega-3 fatty acids may be associated with a higher risk of AMD, there is insufficient evidence from the current literature, with few prospective studies and no randomized clinical trials, to support their routine consumption for AMD prevention. | -1 |
Although this meta-analysis suggests that consumption of fish and foods rich in omega-3 fatty acids may be associated with a lower risk of AMD, there is insufficient evidence from the current literature, with few prospective studies and no randomized clinical trials, to support their routine consumption for AMD prevention. | Although there is no evidence that consumption of fish and foods rich in omega-3 fatty acids may be associated with a lower risk of AMD, there is insufficient evidence from the current literature, with few prospective studies and no randomized clinical trials, to support their routine consumption for AMD prevention. | 0 |
Although this meta-analysis suggests that consumption of fish and foods rich in omega-3 fatty acids may be associated with a lower risk of AMD, there is insufficient evidence from the current literature, with few prospective studies and no randomized clinical trials, to support their routine consumption for AMD prevention. | Although this meta-analysis suggests that consumption of fish and foods rich in omega-3 fatty acids is associated with a lower risk of AMD, there is insufficient evidence from the current literature, with few prospective studies and no randomized clinical trials, to support their routine consumption for AMD prevention. | 1 |
Although ALPI seemed to lower IOP, to decrease the number of topical antiglaucoma medications and widen the iridocorneal angle shortly after the procedure, there is no current evidence of long-term efficacy. | Although ALPI did not seem to lower IOP, to decrease the number of topical antiglaucoma medications and widen the iridocorneal angle shortly after the procedure, there is no current evidence of long-term efficacy. | -1 |
Although ALPI seemed to lower IOP, to decrease the number of topical antiglaucoma medications and widen the iridocorneal angle shortly after the procedure, there is no current evidence of long-term efficacy. | Although ALPI seemed to increase IOP, to decrease the number of topical antiglaucoma medications and widen the iridocorneal angle shortly after the procedure, there is no current evidence of long-term efficacy. | -1 |
Although ALPI seemed to lower IOP, to decrease the number of topical antiglaucoma medications and widen the iridocorneal angle shortly after the procedure, there is no current evidence of long-term efficacy. | Although ALPI seemed to lower IOP, to increase the number of topical antiglaucoma medications and widen the iridocorneal angle shortly after the procedure, there is no current evidence of long-term efficacy. | -1 |
Although ALPI seemed to lower IOP, to decrease the number of topical antiglaucoma medications and widen the iridocorneal angle shortly after the procedure, there is no current evidence of long-term efficacy. | Although ALPI seemed to lower IOP, to decrease the number of topical antiglaucoma medications and narrow the iridocorneal angle shortly after the procedure, there is no current evidence of long-term efficacy. | -1 |
Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. | Latanoprost was not found to be significantly superior to dorzolamide but not brimonidine. | -1 |
Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. | Latanoprost was found to be significantly inferior to dorzolamide but not brimonidine. | -1 |
Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. | There is no evidence that latanoprost is significantly superior to dorzolamide but not brimonidine. | 0 |
Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. | Latanoprost may be significantly superior to dorzolamide but not brimonidine. | 1 |
Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. | Latanoprost was not found to be significantly superior to dorzolamide but not brimonidine. | -1 |
Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. | Latanoprost was found to be significantly inferior to dorzolamide but not brimonidine. | -1 |
Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. | There is no evidence that latanoprost is significantly superior to dorzolamide but not brimonidine. | 0 |
Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. | Latanoprost may be significantly superior to dorzolamide but not brimonidine. | 1 |
However, ocular adverse events were significantly fewer in latanoprost users than in brimonide users. | However, ocular adverse events were not significantly fewer in latanoprost users than in brimonide users. | -1 |
However, ocular adverse events were significantly fewer in latanoprost users than in brimonide users. | However, ocular adverse events were significantly more frequent in latanoprost users than in brimonide users. | -1 |
However, ocular adverse events were significantly fewer in latanoprost users than in brimonide users. | There is no evidence that ocular adverse events were significantly fewer in latanoprost users than in brimonide users. | 0 |
However, ocular adverse events were significantly fewer in latanoprost users than in brimonide users. | However, ocular adverse events were slightly fewer in latanoprost users than in brimonide users. | 1 |
The meta-analysis highlighted that certain mutations of some TLR4 polymorphisms might increase the susceptibility of OAG. | The meta-analysis highlighted that certain mutations of some TLR4 polymorphisms might not increase the susceptibility of OAG. | -1 |
The meta-analysis highlighted that certain mutations of some TLR4 polymorphisms might increase the susceptibility of OAG. | The meta-analysis highlighted that certain mutations of some TLR4 polymorphisms might decrease the susceptibility of OAG. | -1 |
The meta-analysis highlighted that certain mutations of some TLR4 polymorphisms might increase the susceptibility of OAG. | There is no evidence that certain mutations of some TLR4 polymorphisms might increase the susceptibility of OAG. | 0 |
The meta-analysis highlighted that certain mutations of some TLR4 polymorphisms might increase the susceptibility of OAG. | The meta-analysis highlighted that certain mutations of some TLR4 polymorphisms increase the susceptibility of OAG. | 1 |
Treatment with Ozurdex is associated with significant mean improvement in visual acuity. | Treatment with Ozurdex is not associated with significant mean improvement in visual acuity. | -1 |
Treatment with Ozurdex is associated with significant mean improvement in visual acuity. | Treatment with Ozurdex is associated with significant mean decrease in visual acuity. | -1 |
Treatment with Ozurdex is associated with significant mean improvement in visual acuity. | There is no evidence that treatment with Ozurdex is associated with significant mean improvement in visual acuity. | 0 |
Treatment with Ozurdex is associated with significant mean improvement in visual acuity. | Treatment with Ozurdex may be associated with significant mean improvement in visual acuity. | 1 |
The results of this meta-analysis demonstrated that fish consumption can reduce AMD risk. | The results of this meta-analysis demonstrated that fish consumption can not reduce AMD risk. | -1 |
The results of this meta-analysis demonstrated that fish consumption can reduce AMD risk. | The results of this meta-analysis demonstrated that fish consumption can increase AMD risk. | -1 |
The results of this meta-analysis demonstrated that fish consumption can reduce AMD risk. | There is no evidence that fish consumption can reduce AMD risk. | 0 |
The results of this meta-analysis demonstrated that fish consumption can reduce AMD risk. | The results of this meta-analysis demonstrated that fish consumption may reduce AMD risk. | 1 |
Recent evidence suggests that glaucoma may increase the risk of AD. | Recent evidence suggests that glaucoma may not increase the risk of AD. | -1 |
Recent evidence suggests that glaucoma may increase the risk of AD. | Recent evidence suggests that glaucoma may reduce the risk of AD. | -1 |
Recent evidence suggests that glaucoma may increase the risk of AD. | There is no evidence that glaucoma increases the risk of AD. | 0 |
Recent evidence suggests that glaucoma may increase the risk of AD. | Recent evidence suggests that glaucoma increases the risk of AD. | 1 |
Fixed combination therapies are equally safe and effective at lowering IOP as their non-fixed components administered concomitantly. | Fixed combination therapies are not equally safe and effective at lowering IOP as their non-fixed components administered concomitantly. | -1 |
Fixed combination therapies are equally safe and effective at lowering IOP as their non-fixed components administered concomitantly. | Fixed combination therapies are less safe and effective at lowering IOP than their non-fixed components administered concomitantly. | -1 |
Fixed combination therapies are equally safe and effective at lowering IOP as their non-fixed components administered concomitantly. | There is no evidence that fixed combination therapies are equally safe and effective at lowering IOP as their non-fixed components administered concomitantly. | 0 |
Fixed combination therapies are equally safe and effective at lowering IOP as their non-fixed components administered concomitantly. | Fixed combination therapies may be equally safe and effective at lowering IOP as their non-fixed components administered concomitantly. | 1 |
Random-effects meta-analyses failed to detect any significant association of POAG with genetic polymorphisms in CYP1B1, including rs180040, rs1056836, rs10012, rs1056827, rs1056837, and rs2567206. | Random-effects meta-analyses detected significant association of POAG with genetic polymorphisms in CYP1B1, including rs180040, rs1056836, rs10012, rs1056827, rs1056837, and rs2567206. | -1 |
Random-effects meta-analyses failed to detect any significant association of POAG with genetic polymorphisms in CYP1B1, including rs180040, rs1056836, rs10012, rs1056827, rs1056837, and rs2567206. | There is no evidence of significant association of POAG with genetic polymorphisms in CYP1B1, including rs180040, rs1056836, rs10012, rs1056827, rs1056837, and rs2567206. | 0 |
There appears to be no difference in IOP-lowering efficacy between GDDs and cyclophotocoagulation, although GDDs appear to be safer. | There is no difference in IOP-lowering efficacy between GDDs and cyclophotocoagulation, although GDDs appear to be safer. | 1 |
There appears to be no difference in IOP-lowering efficacy between GDDs and cyclophotocoagulation, although GDDs appear to be safer. | There appears to be no difference in IOP-lowering efficacy between GDDs and cyclophotocoagulation, although GDDs appear not to be safer. | -1 |
There appears to be no difference in IOP-lowering efficacy between GDDs and cyclophotocoagulation, although GDDs appear to be safer. | There appears to be no difference in IOP-lowering efficacy between GDDs and cyclophotocoagulation, although GDDs appear to be less safe. | -1 |
There appears to be no difference in IOP-lowering efficacy between GDDs and cyclophotocoagulation, although GDDs appear to be safer. | There appears to be no difference in IOP-lowering efficacy between GDDs and cyclophotocoagulation, although GDDs are safer. | 1 |
AGV and trabeculectomy also seem to provide similar IOP-lowering results with trabeculectomy showing lower failure rates. | AGV and trabeculectomy also provide similar IOP-lowering results with trabeculectomy showing lower failure rates. | 1 |
AGV and trabeculectomy also seem to provide similar IOP-lowering results with trabeculectomy showing lower failure rates. | AGV and trabeculectomy also seem to provide similar IOP-lowering results with trabeculectomy appearing to show lower failure rates. | 1 |
Compared to no treatment, repeated intravitreal injection of anti-VEGF agents in eyes with CRVO macular oedema improved visual outcomes at six months. | Compared to no treatment, repeated intravitreal injection of anti-VEGF agents in eyes with CRVO macular oedema did not improve visual outcomes at six months. | -1 |
Compared to no treatment, repeated intravitreal injection of anti-VEGF agents in eyes with CRVO macular oedema improved visual outcomes at six months. | Compared to no treatment, repeated intravitreal injection of anti-VEGF agents in eyes with CRVO macular oedema negatively affected visual outcomes at six months. | -1 |
Compared to no treatment, repeated intravitreal injection of anti-VEGF agents in eyes with CRVO macular oedema improved visual outcomes at six months. | There is no evidence that compared to no treatment, repeated intravitreal injection of anti-VEGF agents in eyes with CRVO macular oedema improved visual outcomes at six months. | 0 |
Compared to no treatment, repeated intravitreal injection of anti-VEGF agents in eyes with CRVO macular oedema improved visual outcomes at six months. | Compared to no treatment, repeated intravitreal injection of anti-VEGF agents in eyes with CRVO macular oedema might improve visual outcomes at six months. | 1 |
All agents were relatively well tolerated with a low incidence of adverse effects in the short term. | All agents were poorly tolerated with a high incidence of adverse effects in the short term. | -1 |
All agents were relatively well tolerated with a low incidence of adverse effects in the short term. | There is no evidence that all agents were relatively well tolerated with a low incidence of adverse effects in the short term. | 0 |
All agents were relatively well tolerated with a low incidence of adverse effects in the short term. | All agents were very well tolerated with a low incidence of adverse effects in the short term. | 1 |
This meta-analysis summarizes the strong evidence for an association between HTRA1 -512G>A polymorphism and AMD and indicates a co-dominant model of action. | This meta-analysis summarizes the strong evidence for absence of association between HTRA1 -512G>A polymorphism and AMD and indicates a co-dominant model of action. | -1 |
This meta-analysis summarizes the strong evidence for an association between HTRA1 -512G>A polymorphism and AMD and indicates a co-dominant model of action. | This meta-analysis summarizes evidence for an association between HTRA1 -512G>A polymorphism and AMD and indicates a co-dominant model of action. | 1 |
This review found that omega 3 LCPUFA supplementation in people with AMD for periods up to five years does not reduce the risk of progression to advanced AMD or the development of moderate to severe visual loss. | This review found that omega 3 LCPUFA supplementation in people with AMD for periods up to five years reduces the risk of progression to advanced AMD or the development of moderate to severe visual loss. | -1 |
This review found that omega 3 LCPUFA supplementation in people with AMD for periods up to five years does not reduce the risk of progression to advanced AMD or the development of moderate to severe visual loss. | This review found that omega 3 LCPUFA supplementation in people with AMD for periods up to five years does not increase the risk of progression to advanced AMD or the development of moderate to severe visual loss. | -1 |
This review found that omega 3 LCPUFA supplementation in people with AMD for periods up to five years does not reduce the risk of progression to advanced AMD or the development of moderate to severe visual loss. | This review found that omega 3 LCPUFA supplementation in people with AMD for periods up to five years may not reduce the risk of progression to advanced AMD or the development of moderate to severe visual loss. | 1 |
Despite heterogeneity, meta-analysis showed significant and consistent decrease in IOP and medications from baseline to end point in AIT and phaco-AIT. | Despite heterogeneity, meta-analysis showed significant and consistent increase in IOP and medications from baseline to end point in AIT and phaco-AIT. | -1 |
Ex-Press was associated with equivalent efficacy to Trab in lowering IOP. | Ex-Press was not associated with equivalent efficacy to Trab in lowering IOP. | -1 |
Ex-Press was associated with equivalent efficacy to Trab in lowering IOP. | Ex-Press was associated with superior efficacy to Trab in lowering IOP. | -1 |
Ex-Press was associated with equivalent efficacy to Trab in lowering IOP. | There is no evidence that Ex-Press was associated with equivalent efficacy to Trab in lowering IOP. | 0 |
Ex-Press was associated with equivalent efficacy to Trab in lowering IOP. | Ex-Press may be associated with equivalent efficacy to Trab in lowering IOP. | 1 |
Ex-Press was better tolerated than Trab. | Ex-Press was not better tolerated than Trab. | -1 |
Ex-Press was better tolerated than Trab. | Ex-Press was tolerated worse than Trab. | -1 |
Ex-Press was better tolerated than Trab. | There is no evidence that Ex-Press was better tolerated than Trab. | 0 |
The pooled evidence confirmed that, compared with ranibizumab, bevacizumab was associated with equivalent effects on visual acuity at 1 year and with a higher risk of systemic serious adverse events. | The pooled evidence confirmed that, compared with ranibizumab, bevacizumab was not associated with equivalent effects on visual acuity at 1 year and with a higher risk of systemic serious adverse events. | -1 |
The pooled evidence confirmed that, compared with ranibizumab, bevacizumab was associated with equivalent effects on visual acuity at 1 year and with a higher risk of systemic serious adverse events. | There is no evidence that, compared with ranibizumab, bevacizumab was associated with equivalent effects on visual acuity at 1 year and with a higher risk of systemic serious adverse events. | 0 |
The pooled evidence confirmed that, compared with ranibizumab, bevacizumab was associated with equivalent effects on visual acuity at 1 year and with a higher risk of systemic serious adverse events. | The pooled evidence confirmed that, compared with ranibizumab, bevacizumab might be associated with equivalent effects on visual acuity at 1 year and with a higher risk of systemic serious adverse events. | 1 |
The pooled evidence confirmed that, compared with ranibizumab, bevacizumab was associated with equivalent effects on visual acuity at 1 year and with a higher risk of systemic serious adverse events. | The pooled evidence confirmed that, compared with ranibizumab, bevacizumab was associated with equivalent effects on visual acuity at 1 year but not with a higher risk of systemic serious adverse events. | -1 |
The pooled evidence confirmed that, compared with ranibizumab, bevacizumab was associated with equivalent effects on visual acuity at 1 year and with a higher risk of systemic serious adverse events. | The pooled evidence confirmed that, compared with ranibizumab, bevacizumab was associated with equivalent effects on visual acuity at 1 year and with a lower risk of systemic serious adverse events. | -1 |
There was no difference in mean systolic or diastolic diurnal and nocturnal blood pressure between patients with or without progressive visual field loss. | There is no evidence of difference in mean systolic or diastolic diurnal and nocturnal blood pressure between patients with or without progressive visual field loss. | 0 |
This meta-analysis suggests lower cognitive function test scores in patients with AMD, especially with MMSE and Mini-Cog test. | This meta-analysis does not suggest lower cognitive function test scores in patients with AMD, especially with MMSE and Mini-Cog test. | -1 |
This meta-analysis suggests lower cognitive function test scores in patients with AMD, especially with MMSE and Mini-Cog test. | This meta-analysis suggests higher cognitive function test scores in patients with AMD, especially with MMSE and Mini-Cog test. | -1 |
This meta-analysis suggests lower cognitive function test scores in patients with AMD, especially with MMSE and Mini-Cog test. | There is no evidence of lower cognitive function test scores in patients with AMD, especially with MMSE and Mini-Cog test. | 0 |
The literature review confirmed a strong association between current smoking and AMD, which fulfilled established causality criteria. | The literature review confirmed absence of association between current smoking and AMD, which fulfilled established causality criteria. | -1 |
The literature review confirmed a strong association between current smoking and AMD, which fulfilled established causality criteria. | The literature review confirmed moderate association between current smoking and AMD, which fulfilled established causality criteria. | 1 |
There is substantial disagreement between OCT and FFA findings in detecting active disease in patients with nAMD who are being monitored. | There is no substantial disagreement between OCT and FFA findings in detecting active disease in patients with nAMD who are being monitored. | -1 |
There is substantial disagreement between OCT and FFA findings in detecting active disease in patients with nAMD who are being monitored. | There is substantial agreement between OCT and FFA findings in detecting active disease in patients with nAMD who are being monitored. | -1 |
There is substantial disagreement between OCT and FFA findings in detecting active disease in patients with nAMD who are being monitored. | There is no evidence of substantial disagreement between OCT and FFA findings in detecting active disease in patients with nAMD who are being monitored. | 0 |
This meta-analysis showed the evidence that TP53 codon 72 (CC versus CG+GG) and intron 3 16-bp insertion (Ins versus Del) polymorphisms may affect individual susceptibility to POAG. | This meta-analysis showed the evidence that TP53 codon 72 (CC versus CG+GG) and intron 3 16-bp insertion (Ins versus Del) polymorphisms may not affect individual susceptibility to POAG. | -1 |
This meta-analysis showed the evidence that TP53 codon 72 (CC versus CG+GG) and intron 3 16-bp insertion (Ins versus Del) polymorphisms may affect individual susceptibility to POAG. | There is no evidence that TP53 codon 72 (CC versus CG+GG) and intron 3 16-bp insertion (Ins versus Del) polymorphisms may affect individual susceptibility to POAG. | 0 |
This meta-analysis showed the evidence that TP53 codon 72 (CC versus CG+GG) and intron 3 16-bp insertion (Ins versus Del) polymorphisms may affect individual susceptibility to POAG. | This meta-analysis showed the evidence that TP53 codon 72 (CC versus CG+GG) and intron 3 16-bp insertion (Ins versus Del) polymorphisms affects individual susceptibility to POAG. | 1 |
The limited evidence suggests that vitreomacular interface configuration have a significant influence on the visual acuity gain and CMT reduction at 1 year, injection numbers at 2 years in neovascular AMD patients treated with anti-VEGF agents. However, the results of this meta-analysis should be interpreted with caution because of the heterogeneity among study designs. | The limited evidence suggests that vitreomacular interface configuration does not have a significant influence on the visual acuity gain and CMT reduction at 1 year, injection numbers at 2 years in neovascular AMD patients treated with anti-VEGF agents. However, the results of this meta-analysis should be interpreted with caution because of the heterogeneity among study designs. | -1 |
The limited evidence suggests that vitreomacular interface configuration have a significant influence on the visual acuity gain and CMT reduction at 1 year, injection numbers at 2 years in neovascular AMD patients treated with anti-VEGF agents. However, the results of this meta-analysis should be interpreted with caution because of the heterogeneity among study designs. | The limited evidence suggests that vitreomacular interface configuration have a significant influence on the visual acuity decrease and CMT increase at 1 year, injection numbers at 2 years in neovascular AMD patients treated with anti-VEGF agents. However, the results of this meta-analysis should be interpreted with caution because of the heterogeneity among study designs. | -1 |
Trabeculectomy was found to have a greater pressure-lowering effect compared with viscocanalostomy. | Trabeculectomy was not found to have a greater pressure-lowering effect compared with viscocanalostomy. | -1 |
Trabeculectomy was found to have a greater pressure-lowering effect compared with viscocanalostomy. | Trabeculectomy was found to have a lesser pressure-lowering effect compared with viscocanalostomy. | -1 |
Trabeculectomy was found to have a greater pressure-lowering effect compared with viscocanalostomy. | There is no evidence that trabeculectomy has a greater pressure-lowering effect compared with viscocanalostomy. | 0 |
Trabeculectomy was found to have a greater pressure-lowering effect compared with viscocanalostomy. | Trabeculectomy may have a greater pressure-lowering effect compared with viscocanalostomy. | 1 |
However, viscocanalostomy had a significantly better risk profile. | However, viscocanalostomy did not have a significantly better risk profile. | -1 |
However, viscocanalostomy had a significantly better risk profile. | However, viscocanalostomy had a significantly worse risk profile. | -1 |
However, viscocanalostomy had a significantly better risk profile. | There is no evidence that viscocanalostomy had a significantly better risk profile. | 0 |
RBZ and RBZ + Laser had better visual and anatomic outcomes than laser monotherapy in the treatment of DME. | RBZ and RBZ + Laser did not have better visual and anatomic outcomes than laser monotherapy in the treatment of DME. | -1 |
RBZ and RBZ + Laser had better visual and anatomic outcomes than laser monotherapy in the treatment of DME. | RBZ and RBZ + Laser had worse visual and anatomic outcomes than laser monotherapy in the treatment of DME. | -1 |
RBZ and RBZ + Laser had better visual and anatomic outcomes than laser monotherapy in the treatment of DME. | There is no evidence that RBZ and RBZ + Laser had better visual and anatomic outcomes than laser monotherapy in the treatment of DME. | 0 |
RBZ + Laser seemed to be equivalent to RBZ. | There is no evidence that RBZ + Laser is equivalent to RBZ. | 0 |
RBZ + Laser seemed to be equivalent to RBZ. | RBZ + Laser was equivalent to RBZ. | 1 |
The evidence available, however, suggests that at 12 months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. | The evidence available, however, suggests that at 12 months, T&E is inferior to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. | -1 |